Glycosylated Delphinidins, Natural Antioxidants, Functionally Modulate the COX-2/PGE2 Axis and Downregulate MDR1 in Glioblastoma Cells
Authors:
- Constanza CuevasCCConstanza Cuevas
- Yessica NahuelpanYNYessica Nahuelpan
- Darling HaroDHDarling Haro
- Pamela SilvaPSPamela Silva
- Vicente VillagranVVVicente Villagran
- María A. GleisnerMGMaría A. Gleisner
- Flavio Salazar-OnfrayFlavio Salazar-Onfray
- Juan P. MuñozJMJuan P. Muñoz
- Christian PávezCPChristian Pávez
- Noemi Garcia-RomeroNGNoemi Garcia-Romero
- Angel Ayuso-SacidoAAAngel Ayuso-Sacido
- Rody San MartinRMRody San Martin
Open Access
- 13 August 2026
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 15 (8) , 1005
Abstract
The multidrug resistance (MDR) phenotype, mediated by transporters such as MDR1/P-glycoprotein (P-gp), represents a critical obstacle in the treatment of glioblastoma (GB). Natural antioxidants such as glycosylated delphinidins—anthocyanins abundant in Chilean berries, particularly the native species Aristotelia chilensis (maqui)—have emerged as bioactive compounds that modulate inflammation and cancer-related pathways. In this context, the regulation of inflammation-associated signaling pathways, including COX-2 and NF-κB, represents a potential strategy to overcome chemoresistance. In this study, we evaluated the effect of delphinidin-3-glucoside (DEL-3) on the COX-2/PGE2 axis, MDR1 expression, and sensitivity to chemotherapeutic agents in U87-MG and GBM38 glioblastoma cells and in an NOD-SCID xenograft model using ELISA, RT-qPCR, Western blot, and luciferase reporter assays. DEL-3 reduced PGE2 production, consistent with functional modulation of the COX-2/PGE2 pathway, and downregulated MDR1 expression at both transcriptional and protein levels, in agreement with reduced promoter activity. Functionally, combined treatment with DEL-3 and MDR1-substrate chemotherapeutic agents enhanced cytotoxicity in U87-MG cells. Although DEL-3 did not significantly reduce tumor growth in a NOD-SCID xenograft model, MDR1 expression was reduced in treated tumors, indicating in vivo modulation of the target. Overall, these findings suggest that DEL-3, as a natural antioxidant, modulates inflammation-associated mechanisms and downregulates MDR1, thereby potentially enhancing the sensitivity of glioblastoma cells to MDR1-substrate chemotherapeutic agents.Keywords
Funding Information
- FONDECYT POSTDOCTORADO (3220237 ANID)
- Fondecyt Regular (1241275 ANID)
- Fondecyt de Iniciación en investigación 2025 (11250378 ANID)
- High tech innova of the production development corporation (24IAT-272473)
- ANID -FONDEQUIP (EQY230018)
- Millennium Science Initiative Program (ICN09_016/ICN 2021_045)
This publication has 44 references indexed in Scilit:
- Delphinidin modulates neuroinflammation and behavioral deficits in a Parkinson’s disease mouse modelnpj Parkinson's Disease, 2026
- Anthocyanins: From Natural Colorants to Potent Anticancer AgentsFood Science & Nutrition, 2025
- Native berries of Chile: a comprehensive review on nutritional aspects, functional properties, and potential health benefitsJournal of Food Measurement and Characterization, 2020
- Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-gliomaJournal of Neuro-Oncology, 2017
- Cyclooxygenase-2 in glioblastoma multiformeDrug Discovery Today, 2017
- Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency ModelComputational and Structural Biotechnology Journal, 2015
- Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell lineCancer Chemotherapy and Pharmacology, 2009
- Fyn kinase is a direct molecular target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factor-αBiochemical Pharmacology, 2009
- Feedback regulation of cyclooxygenase-2 transcription ex vivo and in vivoBiochemical and Biophysical Research Communications, 2008
- Anthocyanidins inhibit cyclooxygenase-2 expression in LPS-evoked macrophages: Structure–activity relationship and molecular mechanisms involvedBiochemical Pharmacology, 2005